SMMT (Summit Therapeutics Inc.) Stock Market Reviews

crown

search

Read and share opinions on SMMT (Summit Therapeutics Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

SMMT

Summit Therapeutics Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial
Nov 11, 2025
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
Nov 7, 2025
Summit Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress
Nov 3, 2025
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Oct 31, 2025
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025
Oct 31, 2025
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares
Oct 28, 2025
Summit Therapeutics Raises $500 Million in Private Placement
Oct 22, 2025
Company News for Oct 21, 2025
Oct 21, 2025
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab
Oct 21, 2025
Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ...
Oct 20, 2025
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
Oct 20, 2025

Reviews